Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 123 of 1,261
  1. US 11957736

    Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same

    XERIS PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  2. US 11958903

    Single-domain antibodies against LAG-3 and uses thereof

    Nanjing Legend Biotech Co., Ltd · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  3. US 11957687

    Modulators of HSD17B13 and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  4. US 11958908

    Compositions and methods for the depletion of CD117+ cells

    CRISPR THERAPEUTICS AG · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  5. US 11958909

    Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

    Sutro Biopharma, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  6. US 11958893

    Methods for modulating an immune response

    Cue Biopharma, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  7. US 11959096

    Methods for selective inhibition of pluripotent stem cells

    The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services NIH, Office of Technology Transfer · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  8. US 11959080

    Methods and compositions for inhibiting PMP22 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  9. US 11957677

    Cancer treatment using FGFR inhibitors and PLK1 inhibitors

    Cardiff Oncology, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  10. US 11959081

    Transthyretin (TTR) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  11. US 11959084

    Nucleic acid construct

    AUTOLUS LIMITED · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  12. US 11959082

    Dual activity super toxic RNAi active dsRNAs

    Northwestern University · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  13. US 11957737

    Methods of treating microbial infection and inflammation

    The Regents of the University of Colorado · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  14. US 11957655

    Methods of treating hearing loss

    The Regents of the University of California · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  15. US 11958849

    GLS1 inhibitors for treating disease

    The Board of Regents of the University of Texas System · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  16. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Agios Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  17. US 11957754

    Clinical formulations

    Astellas Institute for Regenerative Medicine · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  18. US 11958910

    Bispecific antigen binding molecules that bind HER2, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  19. US 11958862

    Compounds and compositions and uses thereof

    PGI Drug Discovery LLC · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  20. US 11957740

    Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency

    Prime Bio, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  21. US 11958879

    Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  22. US 11958894

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  23. US 11957686

    Compositions for delivery of reboxetine

    AXSOME THERAPEUTICS, INC. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  24. US 11957675

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.